MS Views and News

MS Views and News
Click Logo - MS Views & News is Dedicated to Providing You with Multiple Sclerosis News and Information

Thursday, January 5, 2012

MS in the News: Info on LDN, Stem Cell, CCSVI, Disability, Research and more

If you are having trouble viewing this message, please Click Here
Stu's Views and MS News e-Newsletter
Week of January 5, 2012
 This weeks articles include information on:  LDN, CCSVI,  Stem Cell, Patient Support, Patient Stories and more
  January's Blog Talk Radio
program information is found below
(scroll down please)
 See and Listen to Our Newest
  Podcast, on  Fatigue
  LOOK at OUR BLOG  and look at
our website to see our newest banners
for Pfizer, Synergy,
Research studies, Questcor and others
Found in this newsletter: 
information -and- our
Social Media Information

"Providing You with
'MS Views and News', 
IS What We Do"
 to see our
 Sponsor's banners

            PLEASE Donate:

outbind://235-00000000EBDCF4E43ED0D511850800105A0510E1C46CB000/index.php?option=com_jdonation&view=jdonation&Itemid=102    "MS Views and News" (MSV&N)  is a 501©(3) Not-For-Profit organization as recognized by the Internal Revenue Service
All contributions are tax deductible to the fullest extent allowed by law 


  ~~  MS in the News  ~~    


  • ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ 

  • ================================ 
     EVER need to Contact your MS Pharmaceutical company

    • and cannot remember where you stored the phone number?  
      No need to worry.   
       Just look at any of our e-Newsletters.
    • Scroll to the bottom of the page to find the
    •  information for each of the
    •  Disease Modifying Medications (DMD's)
     MSVN News:
    Returns on JANUARY 25th (Stu's Birthday)
    An MS Neurologist will be online to take questions
    and then we will chat with 
    and Occupational Therapist
    who will discuss Symptom Management 
    at (Click):  StuMSradio  

      See Our Podcast Video Archives by

    SOCIAL MEDIA and Other Learning Methods


     Find us on  Facebook at our  primary page: 


    Friend's of Stu's Views & MS News (For All Affected by MS) Click:   
    For Caregivers, Click:  
    For the Patient with a progressive form of MSClick: 
    and  LOOK for Stuart on Facebook: 


    For the many who ask medical questions to Stuart, please know that Stuart is not a medical doctor. If you have medical questions, please speak with your medical doctor. If asking Stuart his opinion, he can only answer with regards to how something may have affected his life, with His Multiple Sclerosis. 

    We appreciate your continued support and interest in our vision and goals.  

    To read our vision, goals and mission statement, visit


     Pharmaceutical -
        Patient Resources
    Avonex -
    MS ActiveSource
    (800) 456-2255
    (800) 788-1467
    Copaxone - Shared Solutions
    (800) 887-8100
    Extavia - Patient Support 
    (866) 925-2333
    Novartis Gilenya
    Patient Support 
    (877) 408-4974
    Rebif  - MS LifeLines
    (877) 447-3243  ---------------------
    Novantrone - 
    (877) 447-3243
    Tysabri -TOUCH  Program
    (800) 456-2255
     Need Other sources?
      Write to:

     Sponsors for this e-Newsletter and our
    podcast series, have been provided by:  

    OUR MISSION:  'MS Views and News' (MSVN)  is dedicated to the global collection and distribution of current information concerning Multiple Sclerosis.  In collaboration with other organizations, 'MS Views and News' uses state-of-the-art communication channels to provide information for those affected by, or interested in MS.

    -Newsletter Disclaimer:
    ***Editor's Note: The intent of this newsletter is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.



    No comments:

    Post a Comment

    Leave comments only that directly pertain to each article.
    All solicitations will be removed.